Stryker (SYK) recently announced the expansion of its Foot & Ankle portfolio with the introduction of two cutting-edge products — the Osteotomy Truss System (“OTS”) and the Ankle Truss System (“ATS”). Acquired from 4WEB Medical, these new products are designed to enhance surgical precision and improve patient outcome. Both products will be featured at the American Orthopaedic Foot & Ankle Society Annual Meeting in Vancouver during Sept. 11-14, 2024.The addition of the ATS and the integration of Artelon demo ...

会议主要讨论的核心内容 - 公司的骨科和脊柱业务在2024年上半年表现出色 增长8.5%,调整后增长9% [2][3] - 这主要得益于Mako机器人技术的持续推动膝关节业务增长 以及新产品Insignia髋关节干植入物的推出 [3] - 创伤和四肢业务也持续强劲表现 超出公司自身预期 [3] - 公司预计下半年和2025年骨科业务将保持良好增长势头 继续超越市场增速200-300个基点 [4][6][8] 问答环节重要的提问和回答 - 分析师询问公司是如何看待未来手术量的发展 公司表示膝关节和髋关节手术量有望保持中单位数增长 主要受益于人口老龄化和更年轻患者的需求增加 同时也有一定的价格上涨因素 [6][7][8] - 分析师问及公司在价格管理方面的进展 公司表示通过建立客户解决方案部门 提升定价能力和策略 使得价格下降趋缓 未来有望保持这一趋势 [13][14][15] - 分析师询问Mako机器人在手术中心的应用 公司表示Mako在手术中心的渗透率很高 未来可能会考虑针对手术中心需求推出更小巧的版本 [26][27] - 分析师问及Mako在肩关节和脊柱领域的应用进展 公司表示已获得脊柱应用的监管批准 将在第四季度开始临床应用 肩关节应用也在监管审批中 预计将在今年年底开始临床应用 [29][30][31][34] - 分析师询问创伤和四肢业务的发展 公司表示通过专业化经营策略和新产品Pangea的推出 该业务保持强劲增长 未来有望进一步提升市场份额 [55][56][57][60]

A month has gone by since the last earnings report for Stryker (SYK) . Shares have added about 8.8% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Stryker due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Stryker's Q2 Earnings Beat Estimates, Guidance RaisedStryker r ...

Stryker Corporation (SYK) witnessed substantial gains in the year-to-date period. Shares of the company have rallied 19.8% compared with 10.8% growth of the industry. The S&P 500 Composite has risen 17.9% during the same time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Headquartered in Kalamazoo, MI, Stryker is one of the world’s largest medical device companies operating in the global ...

Stryker Corporation (SYK) is well-poised for growth, backed by a robust robotic arm-assisted surgery platform, Mako, and a diversified product portfolio. Meanwhile, an improvement in price also buoys optimism.Shares of this Zacks Rank #3 (Hold) company have risen 18.4% year to date compared with the industry’s 10.5% growth. The S&P 500 Index has increased 18.2% in the same time frame.Stryker, with a market capitalization of $134.6 billion, is one of the world’s largest medical device companies operating in ...

Portage, Michigan, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis. Lumbar spinal stenosis affects millions of people globally and is a leading cause of pain and disability. Patients today are seeking minimally invasive treatment options, valuing reduced re ...

Portage, Michigan, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, at the Encore Boston Harbor. Spencer Stiles, Group President, Orthopaedics and Spine, and Jason Beach, Vice President, Finance and Investor Relations will represent the Company in a session scheduled for 3:00 pm Eastern Time. A simultaneous webcast and replay of the Company’s presentation will be available on Stryker’s website at www.stryker.com. Th ...

Stryker Corporation (SYK) has entered into a definitive agreement to acquire care.ai, a privately held company specializing in artificial intelligence (AI)-assisted virtual care workflows, smart room technology and ambient intelligence solutions. This acquisition will bolster Stryker’s healthcare IT and wirelessly connected medical device portfolio, reinforcing its commitment to providing cutting-edge solutions that address critical challenges in the healthcare sector, such as nursing shortages and staff re ...

Stryker Corporation (SYK) recently announced the launch of its Pangea Plating System, which received FDA clearance in late 2023. Pangea System is likely to provide variable-angle plating for a range of patient demographics, and its portfolio is both extensive and adaptable.With Pangea System on board, Stryker is now the go-to partner for all things trauma-related, including plates, nails, external fixation devices, and more, supported by the company’s committed staff and first-rate service.More on the Pange ...

文章核心观点 - 医疗和外科产品制造商Stryker公司(NYSE: SYK)是急性护理热潮的受益者[6] - 急性护理是短期密集的医院急诊和重症监护室服务,包括创伤护理和手术,当医院护理和住院量激增时,Stryker作为主要供应商受益[6] - 人口老龄化趋势有利于Stryker,因为其产品广泛应用于医院,从口腔卫生、病人清洁到正骨手术机器人等[9] - Stryker的MedSurg和神经技术业务以及正骨和脊柱业务均实现了良好增长[12] 财务表现 - 2024年第二季度,Stryker的每股收益同比增长10.6%至2.81美元,超出分析师预期2美分[11] - 2024年第二季度,公司收入同比增长8.5%至54.2亿美元,超出预期[11] - 公司预计2024年全年每股收益将在11.90美元至12.10美元之间,与市场预期基本一致[17] - 公司预计2024年全年有机销售增长9%-10%,价格因素将有约0.5%的正面影响[17] 股价表现 - 公司股价呈现下降三角形走势,下方支撑位位于323.75美元附近[10] - 分析师给予公司"中性买入"评级,12个月目标价为373.11美元,较当前价格有15.64%的上涨空间[14][15]